Skip to main content
. 2017 Nov 7;136(19):1824–1839. doi: 10.1161/CIRCULATIONAHA.117.028110

Figure 3.

Figure 3.

Loss of imprinting (LOI) of DLX5 in preeclamptic placenta. A, Analysis of mean LOI levels for DLX5 in healthy and preeclamptic placenta samples. Values are presented as a mean±SEM of LOI (control: 0.1943±0.04765, n=16; early-onset preeclampsia [PE]: 0.5661±0.08516, n=12; late-onset preeclampsia: 0.6349±0.08437, n=14). **P<0.001, ***P<0.0001, 1-way ANOVA, Bonferroni multiple-comparisons test. B, Distribution (number) of DLX5 heterozygocities exceeding a particular LOI. C, Allelic expression analysis of the imprinted DLX5 in placenta samples exhibiting the allele-specific expression but no LOI. cDNA of the heterozygous placenta samples for the single nucleotide polymorphism (rs73708843) were sequenced. D, LOI correlated with DLX5 expression in placenta. P=0.046, Spearman rank correlation. E, CpG methylation of DLX5 locus. Log2-fold change of CpG methylation level in preeclampsia (control, n=20; early-onset preeclampsia, n=20). Hypomethylated CpG sites are shown (differentially methylated region at adjusted P≤0.05). F, Pairwise Spearman rank correlation of CpG methylation and DLX5 expression in placenta (control, n=8; early-onset preeclampsia, n=8; false discovery rate: *P<0.05, **P<0.01). gDNA indicates genomic DNA.